Innovent Reports the P-III (CLEAR-1) Study Data of Picankibart for Treating Plaque Psoriasis in Chinese Patients
Shots:
- The P-III (CLEAR-1) trial assesses picankibart's (200mg, Q4W at wk.0, 4 & 8 followed by 200mg/100mg, Q12W) safety & efficacy vs PBO to treat moderate to severe plaque psoriasis patients (n=500)
- Study met the co-1EPs, depicting PASI 90 attained by 80.3% vs 2.0% & sPGA 0/1 attained by 93.5% vs 13.1% at wk.16, sustained for wk.52. Picankibart (200mg, Q12W) showed PASI 90 & sPGA 0/1 in 84.9% & 85.9% of patients, respectively, at wk.52
- The 2EPs were also met for both picankibart groups, incl. the proportions attaining PASI 75, PASI 100, sPGA score of 0 & DLQI score of 0/1 at wk.16. The drug was superior in all these measures, with improvements sustained for wk.52. IND submission to the NMPA is planned for the same indication
Ref: Innovent | Image: Innovent
Related News:- Innovent’s Picankibart (IBI112) Meet its Primary Endpoint in the P-II (CIBI112A201) Study for the Treatment of Plaque Psoriasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
